Arcutis Biotherapeutics announces new data from two posters at 2025 AAD

Arcutis Biotherapeutics (ARQT) announced new data from two posters shared at the 2025 American Academy of Dermatology Annual Meeting, AAD. The first poster presentation details the positive efficacy, patient reported outcomes, and tolerability for the use of once-daily ZORYVE cream 0.15% in adults and children 6 years and older with mild to moderate AD from the INTEGUMENT 1-2 trials who reported a prior inadequate response, intolerance or contraindication to topical corticosteroids, topical calcineurin inhibitors, or crisaborole. At all timepoints assessed during the four-week trial, more than 91% of participants reported no or mild sensation at the application site and investigators reported no irritation or minimal erythema in greater than or equal to 97% of participants in these subgroups. A second poster presentation shares results from the Phase 3 ARRECTOR trial that outlines improvements in patient-reported outcomes with investigational ZORYVE foam 0.3% compared with vehicle in adults and children aged 12 or older with psoriasis of the scalp and body. ZORYVE foam significantly improved quality of life across the 23-component Scalpdex assessment throughout the eight-week study period. Individuals reported an improvement in symptoms as well as a reduction in how psoriasis impacted their daily life.